Immune markers and frailty in older kidney transplant candidates
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how certain immune system markers, called inflammasomes, relate to frailty (physical weakness and vulnerability) in older adults who are candidates for kidney transplantation. The goal is to better understand these markers, which might help improve care for older transplant patients in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 70 years of age or older.
- You must be a candidate for a kidney transplant (either currently being evaluated or already on the waiting list).
- You must be able to give your own informed consent to participate.
- You must be affiliated with or benefit from a social security scheme.
- You must not be currently involved in another research study that prevents participation, and you must not be under guardianship or assisted decision-making.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with advanced kidney disease who are waiting for a transplant. It will check how physical frailty (weakness and slowness) changes over time and how patients feel, using online questionnaires and simple physical tests.
This study looks at frailty (weakness and tiredness) in kidney transplant patients and how it relates to how well the transplanted kidney is working. It may help find ways to improve long-term transplant health.
This study is designed for older adults with advanced kidney disease who are being considered for a kidney transplant. It aims to improve how patients are optimised (made as healthy as possible) before the transplant surgery, which may help with recovery and overall outcomes.
This study looks at how the immune system ages in people over 60 with inflammatory bowel disease (IBD) and how well newer treatments work for them. It aims to find out if immune aging affects treatment success.
This study tests a new way to monitor harmful antibodies after a kidney transplant. It may help prevent transplant rejection over time.
This Phase 1/2 study tests whether transfusions of donated plasma can improve frailty and immune function in older adults. It mainly checks safety first, and also looks for signs that the immune system and overall strength may improve.
Hear when a new Frailty trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.